Hikma Pharmaceutic (OTCMKTS:HKMPF) – Investment analysts at Jefferies Group upped their FY2018 earnings per share estimates for shares of Hikma Pharmaceutic in a research report issued on Thursday. Jefferies Group analyst J. Vane-Tempest now expects that the company will post earnings per share of $0.91 for the year, up from their previous estimate of $0.75. Jefferies Group currently has a “Underperform” rating on the stock. Jefferies Group also issued estimates for Hikma Pharmaceutic’s FY2019 earnings at $0.99 EPS, FY2020 earnings at $1.05 EPS and FY2021 earnings at $1.14 EPS.
Other research analysts also recently issued reports about the company. Zacks Investment Research raised Hikma Pharmaceutic from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. ValuEngine raised Hikma Pharmaceutic from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. Hikma Pharmaceutic has an average rating of “Hold”.
Shares of Hikma Pharmaceutic stock opened at $15.50 on Monday. Hikma Pharmaceutic has a 12 month low of $12.00 and a 12 month high of $26.50.
TRADEMARK VIOLATION NOTICE: “FY2018 Earnings Forecast for Hikma Pharmaceutic (HKMPF) Issued By Jefferies Group” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/19/fy2018-earnings-forecast-for-hikma-pharmaceutic-hkmpf-issued-by-jefferies-group.html.
About Hikma Pharmaceutic
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.